VEKLURY Drug Patent Profile

Which patents cover Veklury, and what generic alternatives are available?

Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are sixteen patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and forty-seven patent family members in forty-nine countries.

The generic ingredient in VEKLURY is remdesivir. One supplier is listed for this compound. Additional details are available on the remdesivir profile page.

DrugPatentWatch^® Generic Entry Outlook for Veklury

Veklury was eligible for patent challenges on October 22, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 8, 2032. This may change due to patent challenges or generic licensing.

There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VEKLURY

International Patents:	347
US Patents:	16
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	34
Clinical Trials:	8
Patent Applications:	3,656
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VEKLURY
What excipients (inactive ingredients) are in VEKLURY?	VEKLURY excipients list
DailyMed Link:	VEKLURY at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VEKLURY

NDA:

214787

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VEKLURY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chiang Mai University	PHASE2
PENTA Foundation	PHASE2
AMS-PHPT Research Collaboration	PHASE2

See all VEKLURY clinical trials

Pharmacology for VEKLURY

Drug Class

SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor

Paragraph IV (Patent) Challenges for VEKLURY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VEKLURY	Powder for Injection	remdesivir	100 mg/vial	214787	1	2025-04-22

US Patents and Regulatory Information for VEKLURY

VEKLURY is protected by sixteen US patents and four FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	VEKLURY	remdesivir	SOLUTION;INTRAVENOUS	214787-002	Oct 22, 2020		DISCN	Yes	No					Y
Gilead Sciences Inc	VEKLURY	remdesivir	SOLUTION;INTRAVENOUS	214787-002	Oct 22, 2020		DISCN	Yes	No					Y
Gilead Sciences Inc	VEKLURY	remdesivir	SOLUTION;INTRAVENOUS	214787-002	Oct 22, 2020		DISCN	Yes	No					Y

EU/EMA Drug Approvals for VEKLURY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Veklury	remdesivir	EMEA/H/C/005622Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19	Authorised	no	no	no	2020-07-03

International Patents for VEKLURY

When does loss-of-exclusivity occur for VEKLURY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

African Regional IP Organization (ARIPO)

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Ecuador

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Israel

Japan

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VEKLURY around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	3269
Australia	2011280910
Australia	2015238851

Supplementary Protection Certificates for VEKLURY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2937350	LUC00193	Luxembourg		PRODUCT NAME: REMDESIVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/20/1459 20200703
2937350	PA2020539	Lithuania		PRODUCT NAME: REMDESIVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/20/1459 20200703
2595980	132020000000176	Italy		PRODUCT NAME: REMDESIVIR O SALE O ESTERE FARMACEUTICAMENTE ACCETTABILE DELLO STESSO(VEKLURY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1459, 20200703

VEKLURY (remdesivir) Market Dynamics and Financial Trajectory: Sales Trend, Pricing, Exclusivity, and Competitive Pressure

Last updated: July 23, 2026

VeKLURY’s revenue trajectory is driven by COVID-19 demand collapse after 2021, payer tightening on inpatient-only use, and rapid competitive displacement by SOC plus substituted antivirals. The brand’s peak monetization window closed with widespread protocol de-escalation, with subsequent performance skewed toward residual hospital/ID procurement and government stock drawdowns rather than steady commercial growth.

How fast did Veklury sales peak and decline after COVID demand fell?

VEKLURY (remdesivir) was commercialized in 2020-2022 as an intravenous antiviral for COVID-19 under EUA then full FDA approvals. Revenue growth followed early hospital uptake, then contracted as (1) patient selection narrowed, (2) clinical guidance shifted to other interventions in many settings, and (3) global public-sector procurement normalized or ended.

What explains the post-peak revenue downturn?

• Evidence accumulation reduced broad use. As mortality and time-to-recovery benefits became context-specific, formularies and clinical pathways limited remdesivir to defined subpopulations (timing from symptom onset, severity bands).
• Treatment ecosystems diversified. Competitive pressure came from other antivirals and from corticosteroid and immunomodulator dominance in many inpatient pathways.
• Price and reimbursement exposure increased. Hospital systems and payers renegotiated procurement terms as volume fell and contracts were re-tendered.
• Government demand cycles ended. Many countries that front-loaded purchasing during surges reduced buys once case incidence stabilized and stocks were replenished.

What is Veklury’s commercial model and where does margin sit?

VEKLURY has been primarily supplied for hospital procurement (buying through wholesalers or direct contract channels in key territories), not retail pharmacy. That structure makes revenue sensitive to:

• tender schedules and contract renewals,
• formulary restrictions by hospital systems,
• government stock drawdowns and emergency reserves.

Are there known revenue concentration risks for Veklury?

• High volatility risk from COVID incidence. Sales correlate with hospital admissions and ICU throughput.
• Procurement-driven pricing risk. Lower utilization forces price concessions or volume commitments.
• Pathway substitution risk. Once clinical standards move away from a drug, rebound is slower than uptake.

How did FDA approvals and labeling changes affect market dynamics?

FDA approval milestones and labeling expansion shaped demand, but later tightening in practice lowered utilization.

What FDA status is Veklury in?

• Veklury is an FDA-approved product for COVID-19 indications that have evolved over time (including inpatient and certain pediatric use contexts, where applicable under the label).

How do labeling boundaries translate to hospital purchasing?

• Hospitals use remdesivir when the patient profile matches label criteria and when internal protocols align.
• Any restriction in timing window or severity category reduces eligible patient volume.
• Pediatric and weight-based dosing can add complexity but can support niche demand when hospitals have relevant protocols.

What competitive forces challenged Veklury after 2021?

VEKLURY’s market share eroded as treatment standards diversified and as oral antivirals and other regimens reduced IV dependence.

Which competitor categories mattered most?

• Oral antivirals for outpatient or early disease stages (reducing the need for IV administration outside the inpatient setting).
• Alternative inpatient antivirals and combination approaches in some regions.
• Non-antiviral regimen dominance in many hospitalized patients (immunomodulators, corticosteroids) that limited remdesivir’s incremental benefit.

How does exclusivity and the patent estate influence long-term supply and pricing?

Long-term brand economics are governed by both patent exclusivity and regulatory exclusivity, plus the reality that remdesivir’s commercial “window” is largely determined by clinical guidelines rather than patent-only dynamics.

What does patent/competition imply for future pricing?

• Patent expiration and generic entry would typically reduce price pressure only after COVID use declines sufficiently that payers prioritize lowest-cost alternatives.
• Even without immediate generic competition, reduced demand compresses pricing power.

When does Veklury lose exclusivity and what generic entry risks exist?

VEKLURY’s near-term market risk is less about whether generics can launch and more about whether demand exists in sufficient scale to matter. Still, generic and biosimilar-style dynamics in small-molecule antivirals can drive discounting once regulatory barriers fall.

Where does risk typically emerge?

• ANDA pathway for small molecules when formulation and manufacturing IP barriers are cleared.
• Section viii paragraph IV challenges (where applicable) can accelerate availability.
• Supply chain normalization can increase substitutability across hospitals and national formularies.

What is the Orange Book status of Veklury and what patents are listed?

Orange Book listing governs the patent-clearing and generic litigation posture. Mapping the Orange Book to the approved indication(s) and formulation is central to assessing generic launch timing.

How to interpret Orange Book impact on commercial trajectory

• If listed patents are only device/method/formulation dependent, generics may carve or design around.
• If composition-of-matter or key process patents are strong and still active, launches face delay.
• Settlement-driven “first generic” entry often occurs around the end of enforceable periods for the most material patents.

What Veklury litigation and settlement activity affects launch timing?

Patent litigation affects generic entry timing, which can alter pricing and revenue in the residual market.

How litigation typically changes the competitive landscape

• If a patentee secures injunctions over formulation or method claims, generic entry is delayed.
• If parties settle with dates, branded pricing typically compresses starting on the settlement launch date.
• If courts narrow claim scope, generic approval can proceed earlier even if key patents remain listed.

What manufacturing and supply chain constraints shape Veklury revenue?

In specialty IV products, supply capacity and quality execution can affect order fill rates, which then affects hospital contract compliance.

What tends to matter commercially

• Raw material supply and sterile manufacturing scale.
• Batch release timelines and regulatory inspections.
• Contract terms that include delivery schedules during surge years.

Supply constraints can create short-term revenue spikes during outbreaks. Post-peak, capacity expansion can oversupply the market, increasing price pressure.

How does Veklury’s financial trajectory compare with other COVID antivirals?

The relevant comparison is not just sales size but post-peak trajectory shape:

• drugs with broader label use tend to hold revenue longer,
• drugs that align with durable inpatient pathways maintain more predictable ordering,
• drugs that are displaced by oral regimens show sharper decline once early disease management shifts outside hospitals.

VEKLURY’s IV-only administration in many settings contributed to sharper volume erosion compared with treatments that can be used earlier in ambulatory pathways.

What commercial levers could extend Veklury revenue?

VEKLURY can only extend revenue if clinical pathways continue to support IV remdesivir in meaningful subgroups.

Levers that typically extend use

• Updated dosing strategies that improve outcomes in specific populations.
• Evidence supporting earlier administration windows or combination regimens.
• Reimbursement alignment and guideline inclusion in high-volume hospital systems.

In practice, post-pandemic, the most effective lever is durable inclusion in local inpatient protocols rather than new regulatory indications.

What Key Takeaways matter for investors and business strategists?

Key Takeaways

• VEKLURY’s financial trajectory is structurally tied to COVID-19 admission intensity and protocol-driven patient selection, not to steady chronic-market demand.
• Post-peak revenue decline reflects protocol de-escalation and displacement by other antivirals and regimen standards, with pricing power pressured by lower utilization.
• Exclusivity and Orange Book patenting can influence generic launch timing, but the dominant driver of near-term revenue is clinical demand contraction.
• Hospital procurement dynamics, tender schedules, and government stock cycle normalization are core to understanding sales volatility.

FAQs

1) Why did VEKLURY revenue fall after its COVID peak?

Protocol de-escalation, narrower patient eligibility, and competitive substitution reduced eligible inpatient volume, shifting demand from broad utilization to targeted use.

2) Is VEKLURY sales driven more by inpatient admissions or by outpatient demand?

VEKLURY is primarily an IV hospital product, so inpatient admissions and hospital procurement cycles are the dominant drivers.

3) Does VEKLURY benefit from label expansion that could extend demand?

Label expansions can support niche utilization, but durable revenue requires sustained guideline inclusion and payer reimbursement alignment for meaningful patient volumes.

4) What determines when generics could pressure VEKLURY pricing?

Generic entry timing depends on enforceable patent periods and Orange Book-listed patents’ litigation/expiration status, but demand contraction sets the ceiling on revenue remaining.

5) What competitive class is the biggest substitute for VEKLURY?

Oral antivirals and alternative inpatient treatment standards can reduce IV antiviral use, particularly once early disease is managed outside the IV inpatient pathway.

References

1. FDA. Approved Drug Products: Veklury (remdesivir). (FDA label and related approval history).
2. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations for remdesivir (Veklury).
3. Securities and Exchange Commission. Gilead Sciences periodic reports (10-K and 10-Q) describing Veklury commercialization and financial performance by period.

DrugChatter Q&A for VEKLURY

Veklury solfobutil ciclodestryn patent?
Gilead sciences veklury wuropean patent office?
Is veklury used in hospitals?
What are the side effects of Veklury for COVID-19?